B. Riley restated their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note issued to investors on Monday, January 8th, Marketbeat reports. B. Riley currently has a $205.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $220.00. B. Riley also issued estimates for Alnylam Pharmaceuticals’ Q4 2017 earnings at ($1.60) EPS, FY2017 earnings at ($5.32) EPS, Q2 2018 earnings at ($1.46) EPS, Q3 2018 earnings at ($1.14) EPS, Q4 2018 earnings at ($1.20) EPS and FY2018 earnings at ($4.90) EPS.
Other research analysts also recently issued research reports about the stock. JMP Securities boosted their target price on shares of Alnylam Pharmaceuticals from $101.00 to $128.00 and gave the company an outperform rating in a research report on Wednesday, September 20th. Barclays boosted their price target on shares of Alnylam Pharmaceuticals from $127.00 to $158.00 and gave the company an overweight rating in a research note on Wednesday, November 8th. FBR & Co assumed coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, October 30th. They set a buy rating and a $150.00 price target for the company. Cowen restated an outperform rating and set a $151.00 price target (up previously from $117.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, November 3rd. Finally, Needham & Company LLC restated a buy rating and set a $152.00 price target (up previously from $125.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, November 3rd. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. Alnylam Pharmaceuticals has an average rating of Buy and an average target price of $121.20.
Alnylam Pharmaceuticals (NASDAQ ALNY) opened at $129.07 on Monday. The company has a quick ratio of 9.83, a current ratio of 9.83 and a debt-to-equity ratio of 0.14. Alnylam Pharmaceuticals has a 1-year low of $35.98 and a 1-year high of $147.63. The company has a market cap of $12,690.00, a PE ratio of -24.58 and a beta of 2.98.
In related news, EVP Akshay Vaishnaw sold 33,666 shares of the company’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $121.46, for a total value of $4,089,072.36. Following the transaction, the executive vice president now directly owns 45,201 shares in the company, valued at $5,490,113.46. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Michael Mason sold 36,745 shares of the company’s stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the completion of the transaction, the vice president now owns 6,352 shares in the company, valued at $835,859.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 274,075 shares of company stock worth $35,356,089. Insiders own 4.30% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. QS Investors LLC grew its position in Alnylam Pharmaceuticals by 59.7% during the second quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 900 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Alnylam Pharmaceuticals by 7.0% in the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 167 shares during the last quarter. Neuberger Berman Group LLC bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth approximately $229,000. Fayerweather Charles bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth approximately $230,000. Finally, Watch Point Trust Co bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth approximately $235,000. Institutional investors own 88.39% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives “Buy” Rating from B. Riley” was originally posted by BBNS and is the property of of BBNS. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://baseballnewssource.com/markets/alnylam-pharmaceuticals-alny-given-new-205-00-price-target-at-b-riley/1814891.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.